Breast cancer chemoprevention--an update.
This article reviews the recent findings of the IBIS-1 and ATAC trials regarding the role of tamoxifen and anastrozole in the chemoprevention of breast cancer. It also emphasises the need to individualise chemoprevention strategies, and to identify high-risk women who are most likely to develop oestrogen receptor (ER)-positive breast cancer. The prevention of ER-negative disease requires further research, and is likely to be challenging.
Mokbel
K
K
Academic Division of Breast Surgery, St. George's Hospital and Medical School, London, UK. kefahmokbel@hotmail.com
Singh-Ranger
G
G
D000328:Adult; D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D005544:Forecasting; D024522:Genes, BRCA2; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage / Q000627:therapeutic use*; D016017:Odds Ratio; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole